Mitsubishi Ufj Kokusai Asset Management Co., Ltd. Fulcrum Therapeutics, Inc. Transaction History

Mitsubishi Ufj Kokusai Asset Management Co., Ltd.

$92.2 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	SELL	$4.2 - $24.0 $74,747 - $427,128	-17,797 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$9.96 - $23.65 $10,507 - $24,950	1,055 Added 6.3%	17,797 $421,000
Q4 2021 Feb 07, 2022	BUY	$14.0 - $28.44 $234,388 - $476,142	16,742 New	16,742 $298,000

Others Institutions Holding FULC

# of Institutions

149

Shares Held

52.2M

Call Options Held

6.91M

Put Options Held

1.9M

Ra Capital Management, L.P. Boston, MA

10.2M
Shares

$44.7 Million
0.51% of portfolio
Tcg Crossover Management, LLC Palo Alto, CA

5.25M
Shares

$22.9 Million
2.43% of portfolio
Black Rock Inc. New York, NY

4.8M
Shares

$21 Million
0.0% of portfolio
Nantahala Capital Management, LLC New Canaan, CT

4.78M
Shares

$20.9 Million
1.01% of portfolio
Vanguard Group Inc Valley Forge, PA

3.27M
Shares

$14.3 Million
0.0% of portfolio

View Full List

About Fulcrum Therapeutics, Inc.

Ticker FULC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,038,900
Market Cap $227M
Description
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...

More about FULC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mitsubishi Ufj Kokusai Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mitsubishi Ufj Kokusai Asset Management Co., Ltd. with notifications on news.

Account